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ta.2013.1Abstract Background: Detection of the primary tumor has a key role in the management of
patients with unknown primary tumors (UPT).
Purpose: The aim of this study is to assess the efﬁcacy of 18F-FDG PET in locating occult pri-
mary lesions in patients with metastatic cervical lymphadenopathy.
Methods: A systematic search was performed by the PubMed/MEDLINE to identify and select
the relevant studies published within the last 20 years (up to 25/08/2011). Reported detection rates,
sensitivities and speciﬁcities were metaanalyzed. Subgroup analyses were performed if results of
individual studies were heterogeneous.
Results: Thirty studies met the inclusion criteria. The overall sensitivity, speciﬁcity and accuracy
rates of FDG-PET in detecting unknown primary tumorswere 80.6%, 82.1%and 81.5% respectively.
Furthermore, FDG-PET detected 33.5% of tumors that were not apparent after conventional
workup. Whereas PET/CT scans’ overall sensitivity, speciﬁcity and accuracy were 82.5%, 80.2%
and 81.4%respectively. Furthermore, PET/CTdetected 30.7%of tumors thatwere not apparent after
conventional workup. There were no signiﬁcant differences between the diagnostic accuracies of
FDGPET and PET/CT scans.
Conclusions: 18F-FDG PET could be useful in patients with UPT for the detection of the primary
tumor. 18F-FDG PET has high sensitivity, indicating the existence of few false-negative results, an
important feature in the management of oncologic patients that could suggest its utility in the initial
stages of the management process.
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8 O. Hassan et al.1. Introduction
Presentation with metastatic cervical lymphadenopathy is
common for patients with squamous cell carcinoma of the
head and neck. In most cases, a thorough head and neck exam-
ination and various imaging modalities determines the primary
site (origin) of the cancer. When clinicians are unable to deter-
mine the origin of the metastatic cervical lymphadenopathy,
the cancer is said to originate from an unknown primary site
(CUP).1
18 Fluorodeoxyglucose (18F-FDG) is an analog of glucose
with major applications in oncology (cancer detection), neurol-
ogy, and cardiology. 18F-FDG is administered intravenously
and is then transported into cells by glucose transporter pro-
teins in a fashion similar to that for unlabeled glucose. Numer-
ous malignant tumors express higher numbers of speciﬁc
membrane transport proteins, with greater afﬁnity for glucose
than normal cells, which permits increased glucose ﬂow into
the cancerous cells.2
Positron emission tomography–computed tomography
(PET–CT) is a medical imaging device which combines in a
single gantry system both PET and an X-ray computed
tomography. While a CT scan provides anatomical detail
(size and location of the tumor, mass, etc.), a PET scan pro-
vides metabolic detail (cellular activity of the tumor, mass,
etc.). Combined PET/CT is more accurate than PET or CT
alone.3
The literature examining the role of PET for the detection
of the unknown primary in patients presenting with metastatic
cervical lymphadenopathy following conventional work-up
presents variable results with some investigators, concluding
that it is highly useful and others the opposite. The reasons
for this variability are no doubt multifactorial; the retrospec-
tive nature of most of these studies as well as the heterogeneity
in terms of workup and patient selection in addition to most of
these studies being small in size and, as such, may on their own
have lacked sufﬁcient statistical power to address this issue
adequately. To overcome this and other limitations, we con-
ducted a meta-analysis with the speciﬁc aim of ﬁnding out
the efﬁcacy of PET imaging in locating the primary site of oc-
cult primary with cervical lymph node metastasis.Table 1 Detailed literature search.
Keywords
PET imaging and unknown primary
PET imaging in unknown primary cancer with neck
disease
PET imaging review and occult primary
PET imaging review and occult primary with cervical
metastasis
PET scan and unknown primary
PET scan and occult primary
PET–CT and unknown primary
PET–CT and occult primary
Cervical lymph node metastases from occult primary
Diagnosis of head and neck cancer with occult primary
Diagnosis of head and neck cancer with unknown primary
The role of pet imaging in diagnosis of occult primary with
cervical lymph node metastasis
Total2. Methods
2.1. Search for relevant studies
Using MEDLINE database (www.pubmed.com), we conducted
a systematic literature search to identify relevant studies pub-
lishedwithin the last 20 years (up to 25/08/2011), which evaluated
the role of PET imaging in diagnosis of occult primary with cer-
vical lymph node metastases. Disease-speciﬁc search terms (Un-
known primary, Occult Primary, Cervical Lymph node
metastasis, or Diagnosis and management of head and neck can-
cer with unknown primary) were combined with diagnostic
modality speciﬁc search terms (PET scan, PET/CT, PET imaging
or the role of PET imaging in the diagnosis of occult primarywith
cervical lymph nodemetastasis) in all our searches. The electronic
searches were supplemented by scanning the reference lists from
retrieved articles to identify additional studies thatmayhave been
missed during the initial search. It was decided to include only
those studies which are published in English language or trans-
lated toEnglish language, dealingwith human subjects, including
radiological procedureswhere 18F-FDGPETwas comparedwith
CT orMRI after negative results in conventional diagnostic pro-
cedures, histo-pathological study should be done to conﬁrm the
results of PET imaging and ﬁne needle aspiration biopsy done
to themetastatic lymphnode should indicate non-lymphomatous
malignancy. In studies that included patients with different dis-
eases, only those patients with CUPwithmetastatic cervical lym-
phadenopathy were included. Excluded articles: are those articles
whichmiss one ormore of the above mentioned inclusion criteria
especially if 18F-FDG PET was performed when all diagnostic
procedures (including CT orMRI) carried out did not detect pri-
mary tumor (because the period between performance of the
PET scan and the CT or MRI was not short enough to be rea-
sonably sure that the target condition (occult primary) did not
change between the two tests), duplicated studies or those out-
dated by subsequent ones.
2.2. Study selection and data abstraction
From each relevant article, we abstracted the following
information: type of the study (prospective, retrospective,Number of articles and
their abstracts
Potentially
eligible studies
423 30
52 30
55 31
10 6
347 23
169 17
172 13
92 10
202 19
660 25
1007 37
8 8
3197 249
The role of FDG PET in the diagnosis of occult primary with cervical lymph node metastases: A meta-analysis study 9systematic review, meta-analysis or randomized control), num-
ber of patients (population of the study) having cervical lymph
node metastases from occult primary sites, nature of the inter-
vention (PET scan, PET–CT scan and routine work up), out-
come and results (true and false positive cases). On the basis of
their design, 2 types of studies were differentiated; (type I):
where 18F-FDG PET was performed after all diagnostic proce-
dures including CT or MRI were performed and did not detect
the primary tumor whereas, in (type II), 18F-FDG PET was
compared with CT or MRI in a double-blind study that in-
cluded UPT patients with metastatic cervical lymphadenopa-
thy who had presented negative results for primary tumor
detection in all of the following conventional diagnostic
procedures (if performed in each particular patient): (a) careful
clinical history and complete physical examination; (b) labora-
tory analysis; (c) endoscopic evaluations; (d) surgical explora-
tion, biopsy, or ﬁne-needle aspiration cytology of suspicious
lesions.
To calculate sensitivity and speciﬁcity, the cases with an
area of increased FDG uptake and positive histology were
considered true positives; the cases without FDG uptake, with
negative ‘‘random’’ biopsies of the tonsils, base of the tongue
and nasopharynx have been considered true negatives if the
primary tumor remained unknown in the follow-up. The cases
with increased FDG uptake but negative histology were con-
sidered false positives. Finally, false negatives were the cases
with positive histology, but negative FDG PET.
2.3. Statistical methods
All analyses were conducted using the software: Review Man-
ger version 5.2.4
3. Results
Our search identiﬁed 3197 potentially relevant studies in MED-
LINE (Table 1). Out of them, there were 249 potentially eligible
studies. We excluded 193 of the 249 studies because they miss
one or more of the above mentioned inclusion criteria or were
duplicated or were outdated by other more recent ones. Thus,
56 studies remained for possible inclusion and were retrieved
in full text version. After reviewing the full article, 26 studies
were excluded for the following reasons: some of themwere sys-
tematic review, essay, or case report studies while others were
containing non-occult primary tumors, mixed primary tumors
(both known and unknown tumors), or cervical and extra-cervi-
cal metastases and we cannot differentiate between these data
from results. Still other studies were type 1 studies, or containing
lymphomatousmetastases or the pathological conﬁrmation was
not obtained in all cases discovered by PET. This process left 30
original articles which were then used for further analyses.
3.1. Study description
The 30 included studies contain 1087 patients. Out of them,
367 patients were excluded because they missed one or more
of the previously mentioned inclusion criteria. This process left
720 patients for meta-analysis. The age of the patients ranged
from 26 to 95 years, with mean age of 60.5 years. The propor-
tion of males (562) to females (158) ranged from 78% to 22%
(Table 2).3.2. Analysis of included articles
We divided the included articles into 3 groups according to
whether PET scan or PET–CT scan was done alone or in com-
bination for the patients in comparison to CT scan (Table 3).
– Group A: In this group, the patients underwent PET scan
and CT scan. This group includes 589 patients which repre-
sents the population of 25 studies (1 to 25). The detection
rate for CT scan was 37 (6.3%) primary sites out of 589
patients while PET scan detection rate was 187 (31.7%),
primary sites out of 589 patients. These results were
obtained from 2 subgroups:
 Subgroup A1: This represents type I studies. This sub-
group includes 410 patients which represents the popu-
lation of 17 (1 to 17) studies. In this subgroup CT scan
failed to detect any primary site, while PET scan detec-
ted 127 (31%) primary tumor sites out of 410 patients.
 Subgroup A2: This represents type 2 studies. This sub-
group includes 179 patients which represents the popu-
lation of 8 (18 to 25) studies (Table 4). In this subgroup
CT scan detected 37 (20.7%) primary tumor sites out of
179 patients, while PET scan detected 60 (33.5%) pri-
mary tumor sites out of 179 patients.Themeta-analysis is done only for SubgroupA2 (type 2 stud-
ies) to evaluate the role of PET scan in detection of occult pri-
mary with cervical nodal metastases (Fig. 1), because in
Subgroup A1 (type 1 studies) the 2 modalities were not done
at the same time (the PET scan is done after failure of CT
scan to detect any primary tumor site). The comparison is
signiﬁcant in favor for the use of PET scan in detection of
occult primary with cervical nodal metastases.
– Group B: In this group, the patients underwent PET–
CTscan and CT scan. This group includes 188 patients
which represents the population of 8 studies (numbers 17
and from 24 to 30). The detection rate for CT scan was
16 (8.5%) primary sites out of 188 patients while PET–
CT scan detection rate was 80 (42.6%) primary sites out
of 188 patients. These results were obtained from 2
subgroups:
 Subgroup B1: This represents type I studies. This sub-
group includes 87 patients which represents the popu-
lation of 5 (numbers 17 and from 27 to 30) studies. In
this subgroup CT scan failed to detect any primary site,
while PET–CT scan detected 49 (31%) primary tumor
sites out of 87 patients.
 Subgroup B2: This represents type 2 studies. This sub-
group includes 101 patients which represents the popu-
lation of 3 (numbers 24 to 26) studies (Table 5). In this
subgroup CT scan detected 16 (15.8%) primary tumor
sites out of 101 patients, while PET–CT scan detected 31
(30.7%) primary tumor sites out of 101 patients.The
meta-analysis is done only for Subgroup B2 (type 2 st-
udies) to evaluate the role of PET–CT scan in detection
of occult primary with cervical nodal metastases (Fig. 2),
because in Subgroup B1 (type 1 studies) the 2 modalities
were not done at the same time (the PET–CT scan is
done after failure of CT scan to detect any primary tu-
mor site). The comparison is signiﬁcant in favor for the
use of PET/CT scan in detection of occult primary with
cervical nodal metastases.
Table 2 The general patient characteristics of 30 included articles.
Study number Author Year Number of patients Patients excluded Sex Age range (years)
M F
1 Rege et al.5 1994 60 56 3 1 59–43
2 Braams et al.6 1997 13 9 4 39–60
3 Kole et al.7 1998 29 13 12 4 37–77
4 Greven et al.8 1999 17 4 10 3 41–76
5 Lassen et al.9 1999 20 9 4 7 26–75
6 Stokkel et al.10 1999 10 1 6 3 44–81
7 Bohuslaviski et al.11 2000 53 9 28 16 38–82
8 Jungehulsing et al.12 2000 27 1 23 3 36–74
9 Kresnik et al.13 2001 54 39 12 3 49–73
10 Johansen et al.14 2002 42 27 15 35–80
11 Fogarty et al.15 2003 21 2 12 7 43–85
12 Stoeckli et al.16 2003 18 16 2 33–68
13 Miller et al.17 2005 27 1 24 2 39–78
14 Johansen et al.18 2008 67 7 44 16 32–78
15 Miller et al.19 2008 32 1 27 4 39–81
16 Yabuki et al.20 2010 26 2 21 3 37–82
17 Keller et al.21 2010 77 68 9 40–80
18 Aassar et al.22 1999 17 2 13 2 39–87
19 Hansono et al.23 1999 133 113 17 3 40–72
20 Safa et al.24 1999 14 14 – 48–71
21 Regelink et al.25 2002 62 12 37 13 38–74
22 Mevio et al.26 2004 11 1 9 1 46–72
23 Padovani et al.27 2009 13 10 3 46–82
24 Gutzeit et al.28 2005 45 27 13 5 29–95
25 Nassenstein et al.29 2007 39 31 8 39–89
26 Roh et al.30 2009 44 37 7 39–73
27 Nanni et al.31 2005 21 15 5 1 41–87
28 Ambrosini et al.32 2006 38 29 5 4 41–77
29 Wartski et al.33 2007 38 9 22 7 36–80
30 Solav and Halnaik34 2009 19 14 3 2 40–63
Pooled data 1087 367 562 158
10 O. Hassan et al.– Group C: In this group, the patients underwent PET scan,
PET–CT scan and CT scan. This group represents type 2
studies and includes 57 patients which represent the popula-
tion of 2 studies (24 and 25) (Fig. 3). CT scan discovered 9
(15.8%) primary sites out of 57 patients, PET scan discov-
ered 15 (26.3%) primary sites out of (57) patients while
PET–CT scan detected 17 (29.8%) primary sites out of
(57) patients (Table 6). The comparison is non-signiﬁcant
for both PET scan and PET/CT scan.
3.3. Diagnostic accuracy
The detection rate of PET scan for occult primary with cervical
nodal metastases is calculated from all positive results of PET
scan included from study numbers 1–25 (type 1 and type 2
studies). The true positive results were (187) out of (589) pa-
tients (31.7%), false-positive results were (64) out of (589) pa-
tients (10.9%), false-negative results were (41) out of (589)
patients (7%) and the true negative results were (293) out of
(589) patients (49.7%) (Table 7). The sensitivity of PET scan
for the diagnosis of occult primary with cervical nodal metas-
tases was (80.6%), speciﬁcity (82.1%), accuracy (81.5%), posi-
tive predictive value (74.5%) and negative predictive value
(86.7%) (Table 7).The detection rates of PET–CT scan for occult primary
with cervical nodal metastases are calculated from all positive
results of PET–CT scan included from studies 17; 24–30 (type
1 and type 2 studies). The true positive results were (80) out of
(188) patients (42.6%), the false-positive were (18) out of (188)
patients (9.6%), the false negative results were (17) out of (188)
patients (9%), and the true negative true negative results were
(73) out of (188) patients (38.8%) (Table 8). The sensitivity of
PET–CT scan for the diagnosis of occult primary with cervical
nodal metastasis was (82.5%), speciﬁcity (80.2%), accuracy
(81.4%), PPV (81.6%) and NPV (81.1%) (Table 8).3.4. Primary tumor histopathology
The commonest histopathological type of the lymph node
and primary tumors detected is squamous cell carcinoma
with 140 (68.6%) sites out of 204 sites then adenocarcinoma
with 32 (15.7%) sites out of 204 sites. The least histopatholo-
gical types were Papillary and Muco Epedermoid carcinoma
(0.5 each%).3.5. Primary tumor location
The most common location for the primary tumor site de-
tected with PET imaging was the tonsils with 50 (21.6%) sites
Table 3 The summary of detection rates of PET imaging (PET scan and PET–CT scan) in 30 included articles.
No. Study Pts. No. PET scan PET–CT
TP FP FN TN TP FP FN TN
1 Rege et al. (1994)5 4 2 0 0 2 – – – –
2 Braams et al. (1997)6 13 4 0 1 8 – – – –
3 Kole et al. (1998)7 16 4 0 3 9 – – – –
4 Greven et al. (1999.8 13 1 5 0 7 – – – –
5 Lassen et al. (1999)9 11 5 3 1 2 – – – –
6 Stokkel et al. (1999)10 9 5 3 0 1 – – – –
7 Bohuslaviski et al. (2000)11 44 15 7 1 21 – – – –
8 Jungehulsing et al. (2000.12 26 6 3 0 15 – – – –
9 Kresnik et al. (2001)13 15 11 0 0 4 – – – –
10 Johansen et al. (2002.14 42 10 10 1 21 – – – –
11 Fogarty et al. (2003)15 19 1 5 0 13 – – – –
12 Stoeckli et al. (2003)16 18 5 1 3 9 – – – –
13 Miller et al. (2005)17 26 8 1 4 13 – – – –
14 Johansen et al. (2008)18 60 18 2 3 27 – – – –
15 Miller et al. (2008.19 31 9 1 0 21 – – – –
16 Yabuki et al. (2010)20 24 9 3 1 11 – – – –
17 Keller et al. (2010)21 77 39 14 7 4 14 – – – –
38 – – – – 21 1 4 12
18 Aassar et al. (1999)22 15 7 3 5 0 – – – –
19 Hansono et al. (1999)23 20 7 0 0 13 – – – –
20 Safa et al. (1999.24 14 3 2 0 9 – – – –
21 Regelink et al. (2002)25 50 16 0 0 34 – – – –
22 Mevio et al. (2004)26 10 5 1 0 4 – – – –
23 Padovani et al. (2009)27 13 7 2 3 1 – – – –
24 Gutzeit et al. (2005)28 18 5 2 11 10 6 1 10 11
25 Nassenstein et al. (2007)29 39 10 3 1 25 11 4 0 10
26 Roh et al. (2009)30 44 – – – – 14 5 2 23
27 Nanni et al. (2005)31 6 – – – – 5 1 0 0
28 Ambrosini et al. (2006)32 9 – – – – 7 2 0 0
29 Wartski et al. (2007)33 29 – – – – 13 4 1 8
30 Solav and Halnaik (2009)34 5 – – – – 3 0 0 2
Total 720 187 64 41 293 80 18 17 73
No. = number of the study, Pts. No. = number of patients in the study, TP = true positive, FP = false positive, FN= false negative,
TN= true negative.
Table 4 Reported occult primary tumor detection in 8 studies comparing CT scan versus PET scan.
No. Study Pts. No. CT scan PET scan
18 Aassar et al. (1999)22 15 5 (33.3%) 7 (46.7%)
19 Hansono et al.23 20 4 (20%) 7 (35%)
20 Safa et al. (1999)24 14 1 (7.1%) 3 (21.4%)
21 Regelink et al. (2002)25 50 12 (24%) 16 (32%)
22 Mevio et al. (200426 10 3 (30%) 5 (50%)
23 Padovani et al. (2009)27 13 3 (23.1%) 7 (53.8%)
24 Gutzeit et al. (200528 18 4 (22.2%) 5 (27.8%)
25 Nassenstein et al. (2007)29 39 5 (12.8%) 10 (26.3%)
– Total 179 37 (20.7%) 60 (33.5%)
Pts. No. = patients numbers, No. = number of the study.
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of 232 sites then base of the tongue with 32 (13.8%) sites out of
232 sites, hypo-pharynx with (28) sites out of (232) sites
(12.1%), naso-pharynx with (16) sites out of (232) sites
(6.9%), oro-pharynx with (12) sites out of (232) sites (5.2%),
larynx with (7) sites out of (232) sites (3%), esophagus with
(7) sites out of (232) sites (3%), parotid gland with other sali-
vary glands with (4) sites out of (232) sites (1.7%), ﬂoor of the
mouth with (6) sites out of (232) sites (2.6%), pyriform with (3)sites out of (232) sites (1.3%), maxillary sinus with (3) sites out
of (232) sites (1.3%), epiglottis with (2) sites out of (232) sites
(0.9%) and thyroid gland with (2) sites out of (232) sites
(0.9%) and there are miscellaneous sites outside the head
and neck such as the chest skin, liver, kidney, testis, prostate,
colon and pancreas, these together represent (19) sites out of
(232) sites (9.6%). Infraclavicular primary tumors include
those found in the lung, esophagus and the miscellaneous
group (67 out of 232, 29%).
Figure 1 Forest plot of comparison between PET scan versus CT scan in detection of occult primary with cervical lymph node
metastasis. It is signiﬁcant as Z = 2.75 > 2 and P = 0.006 < 0.05.
Table 5 Reported occult primary tumor detection in 3 studies comparing PET–CT scan versus CT scan.
No. Study Pts. No. CT scan PET–CT
24 Gutzeit et al. (2005)28 18 4 (22.2%) 6 (33.3%)
25 Nassenstein et al. (2007)29 39 5 (12.8%) 11 (28.2%)
26 Roh et al. (2009)30 44 7 (15.9%) 14 (31.8%)
– Total 101 16 (15.8) 31 (30.7%)
Pts. No. = patients numbers, No. = number of the study.
12 O. Hassan et al.4. Discussion
Several reports in the literature describe the efﬁcacy of FDG-
PET in detecting unknown primary tumors in patients with
cervical metastases. Most of these studies, however, are limited
in size and have reported varying results. Our objective in the
current metaanalysis is to compile all the existing literature on
this topic to help guide clinical decision-making regarding the
use of FDG-PET in CUP.
In our study, 18F-FDG PET presents high sensitivity
(80.6%), speciﬁcity (82.1%) and accuracy (81.5) in discovering
occult primary tumor with cervical metastases in 589 patients
indicating the existence of few false-negative and false positive
results. This is important in the management of oncologic pa-Figure 2 Forest plot of comparison between PET–CT versus CT in de
signiﬁcant as Z = 2.46 > 2 and P=0.01 < 0.05.tients and suggests more beneﬁts could be obtained if 18F-
FDG PET was performed in the initial stages of the manage-
ment process.
Our results are concordant with Rusthoven et al. (2004)35
who reported 88.3% sensitivity in 302 patients.
Our results are discordant with Neider et al. (2001)36 where
they reviewed (8) studies involving a total of (122) patients
with cervical lymph node metastases from an unknown pri-
mary. Their analysis revealed a reduced speciﬁcity (62%),
and accuracy (69%) compared with the results reported in
our study. This discrepancy can be attributed to the inclusion
by Nieder and colleagues36 of one study in which FDG-single-
photon emission CT (FDG-SPECT) was used and to the dif-
ference in the sizes of the data sets. A subsequent review by Fo-tection of occult primary with cervical lymph node metastasis. It is
Figure 3 Forest plot of comparison between PET–CT scan versus PET scan in detection of occult primary with cervical lymph node
metastasis. It is not signiﬁcant as Z= 0.42 < 2 and P=0.68 > 0.05.
Table 7 Reported true positive, false positive, false negative, true negative results of both PET scan and PET–CT scan.
Diagnostic tool True positive (%) False positive (%) False negative (%) True negative (%)
PET scan 187 (31.7%) 64 (10.9%) 45 (7.6%) 293 (49.7%)
PET–CT 80 (42.6%) 18 (9.6%) 17 (9%) 73 (38.8%)
Table 6 Reported occult primary tumor detection in 2 studies comparing CT scan, PET scan and PET–CT scan.
No. Study Pts. No. CT scan PET scan PET–CT scan
24 Gutzeit et al. (2005)28 18 4 (22.2%) 5 (27.8%) 6 (33.3%)
25 Nassenstein et al. (2007)29 39 5 (12.8%) 10 (25.6%) 11 (28.2%)
– Total 57 9 (15.8) 15 (26.3%) 17 (29.8%)
No. = number of the study, Pts. No. = patients numbers.
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ies from the review conducted by Neider et al.)36 and data
from a cohort of 21 patients treated at the reviewers’ own insti-
tution. That review reported a similar primary tumor detection
rate. However, it also included FDG-SPECT data from two
studies, resulting in reduced speciﬁcity. The current study goes
beyond these previous reviews by including a larger data set
and by using only FDG-PET imaging data.
The rate of primary tumor detection by FDG-PET in the
current study (33.5%) was slightly higher than that reported
by Fogarty et al. (2003)15 (22.5%). More impressive was the
difference in speciﬁcity between the current review (82.1%)
and the review conducted by Neider et al.36 (62%). The lower
false-positive rate in the current study was attributable in part
to the exclusion of data from FDG-SPECT studies. Despite
this improvement, however, low speciﬁcity remains the most
notable weakness of FDG-PET. False positives mean that
the patient is submitted to unnecessary investigation and
biopsy, with all the inherent morbidity and cost. False posi-
tives may not always be due to a problem with the PET study
per se. Proposed reasons for the high false-positive rate includeTable 8 Diagnostic performance of FDG-PET scan and PET–CT
Diagnostic tool Sensitivity (%) Speciﬁcity (%) Positive predi
PET scan 80.6 82.1 74.5
PET–CT 82.5 80.2 81.6physiologic uptake in the tonsils, reactive lymph nodes, and
muscles of mastication. Less commonly, FDG accumulation
can occur in patients with sarcoidosis, granulomatous disease,
and benign tumors of the salivary glands (Greven et al.8 and
Hanasono et al.23). Stokkel et al.10 have also suggested that re-
cent mucosal biopsy in the workup of unknown primaries can
cause a tissue repair reaction with a consequent increase in
FDG uptake. Finally, Greven et al.,8 suggested that the high
false-positive rate also may be attributable to a geographic
miss by PET-directed biopsy, which could be avoided if there
was co-registration involving CT- or MR-PET fusion.
In the current study, FDG-PET exhibited 80.6% sensitivity
in the detection of primary tumors in agreement with Neider
et al.36 (82%). Kole et al.,7 have suggested several possible
causes for false-negative results; disruption of the signal-to-
noise ratio caused by high background uptake, especially in
the brain, can disrupt the detection of a tumor, and in addi-
tion, well differentiated tumors have been shown to have a
lower rate of FDG uptake. Kole and colleagues7 have also sug-
gested that small tumors that are below the resolution of FDG
PET can lead to false-negative results. Nonetheless, the highscan. In primary tumor detection.
ctive value (%) Negative predictive value (%) Accuracy (%)
86.7 81.5
81.1 81.4
14 O. Hassan et al.sensitivity of FDG-PET in the current study can be attributed
to the large number of true-negative results. In our analysis,
60.6% of patients (357 of 589) never had a primary tumor
found, and FDG-PET yielded true-negative ﬁndings in
49.7% of all patients (293 of 589 patients). Some have specu-
lated that the failure to detect a primary tumor after extensive
workup may be the result of phenomena such as spontaneous
regression or immune-mediated destruction of the primary le-
sion (Jungwhulsing et al.12).
The possible mechanisms why PET demonstrates the nodal
disease well but not the primary in head and neck tumor. Dis-
covery depends on a high tumor uptake compared with a low
background uptake. This may exist in the nodal areas but not
in the area of the primary tumor. Also, the biology of the tu-
mor cells in the nodal regions may be different from that of the
primary. The primary tumor may have been removed unknow-
ingly (e.g., previous treatment of a skin primary tumor) or may
have regressed spontaneously. When a small PET-avid tumor
does exist, the detection is excellent, with lesions less that
1 cm being discovered (Keyes et al.37).
Mukherji et al.,38 comment on their work with 19 patients
that re-reading of the initial PET scan by their most experienced
nuclear medicine radiologist resulted in a change of the PET re-
sult in two patients, meaning there was intraobserver variability
even at an experienced level. Intra and interobserver variability
is present at all levels of the diagnostic workup of a patient with
an unknown primary tumor. The ﬁnding of a primary tumor de-
pends on thoroughness and experience of those who are per-
forming the initial clinical, endoscopic, and radiologic
examinations. In an institution in which there is a depth of expe-
rience and thoroughness in all of these areas, the chance of a tu-
mor still being undetected after all the pre-PET scan workup is
low. The PET scan will then have less chance of ﬁnding a pri-
mary tumormissed by the previous investigations andmay seem
less efﬁcient than in a center in which the previous examinations
are not performed as thoroughly or by staff who are not as expe-
rienced. This may be one factor in the differences in the pickup
of primary tumor by the PET scans between the studies. Rather
than advocate PET scanning for unknownprimary tumor detec-
tion in all cases, it would be of more beneﬁt to ensure that the
initial diagnostic workup was done thoroughly and by experi-
enced personnel.
In our study, PET/CT presents high sensitivity (82.5%),
speciﬁcity (80.2%) and accuracy (81.4) in discovering occult
primary tumor with cervical metastases in 188 patients.
False-positive rates could be reduced by co registration of
PET, which possesses physiologic imaging capabilities, and
CT, which possesses anatomic imaging capabilities. The addi-
tion of CT would allow the assessment of anatomic distortion
by tumors at sites with increased FDG uptake.
In our study, a comparison between the 3 modalities (CT
scan, PET scan and PET–CT) was done in only 2 studies (57
patients). The primary tumor detection for PET scan
(26.3%) and PET–CT scan (29.8%) has nearly equal results.
However the result of the meta-analytical study was not signif-
icant due to the small number of patients.
Bar-Shalom et al.,39 demonstrated the superiority of com-
bined PET/CT compared with either FDG-PET or CT alone
in the detection of malignant disease in the head and neck
and at other sites. In addition, Wong et al.,40 demonstrated,
in a small series, that coregistered CT/MRI and PET correctly
staged primary head and neck carcinoma in 17 of 18 patientsand correctly staged recurrent disease in 9 of 10 patients. In
a larger study that included a subset of patients with CUP,
Antoch et al.,41 found that combined PET/CT led to accurate
staging in 10 of the 12 patients who had CUP, whereas MRI
alone led to accurate staging in only 8 of these 12 patients.
The additional anatomic data obtained using combined PET/
CT would also increase the accuracy of FDG-PET-directed
biopsies. This would be expected to lead to an increase in diag-
nostic accuracy and to a decrease in the number of false-posi-
tive results caused by inaccurate biopsy ﬁndings at suspicious
sites.8
In our study the most common histological types are squa-
mous cell carcinoma 68.6%, then adenocarcinoma 15.7%,
undifferentiated carcinoma 11.3% and this comes in agree-
ment with Rusthoven et al. (2004)35 and study numbers (48,
59, 913, 1519, 1923, 2125, 2529, 2630, 2731, 2933, 3034).
Our histopathological ﬁnding is concordant with Lee et al.
(1991),42 who stated that: In the head and neck, approximately
(60%) of such occult primaries represent squamous cell carci-
noma. Thirty percent are adenocarcinomas and the remainders
are tumors originating in the thyroid gland, melanoma of the
skin and mucosa, and poorly differentiated carcinoma.
If the metastases are from a squamous cell carcinoma, the
primary is found in the head and neck region in the majority
of cases. Metastatic adenocarcinoma most often originates in
a primary tumor below the clavicles, such as in the lung, the
gastrointestinal (GI) tract, the genito-urinary (GU) tract,
breast, and pancreas. However, a small number of these ade-
nocarcinomas may originate in the head and neck from the sal-
ivary glands, paranasal sinuses, and the nasal cavity (Otto and
Otto43).
Our ﬁndings regarding primary tumor locations are con-
sistent with those made in previous studies (48, 610, 1115,
1317, 1519, 1620, 1721, 1822, 2327, 2630, and 2832). Among
head and neck primaries, tumors of the tonsils (21.6%),
and the base of the tongue (13.8%), were the most prevalent
in the current analysis. This is concordant with Mendenhall
et al.,44 who reported that tumors of the tonsils and the base
of the tongue accounted for 43% and 39% of all primary
tumors, respectively. Data from the current study also sug-
gest a lower incidence of primary tumors of the nasophar-
ynx (6.9%), hypopharynx (12.1%), and larynx (3%) than
has been previously reported in the literature on CUP. Men-
denhall et al.,44 suggest that the decreased incidence of un-
known tumors at these locations can be attributed to the
increased sensitivity of ﬁberoptic endoscopes and anatomic
imaging (CT/MRI) in the detection of primary tumors at
these sites. In contrast, tumors of the tonsils and base of
the tongue can resemble lymphoid tissue and thus can be
more difﬁcult to detect with conventional workup. In the
current study, 29% of all primary tumors in patients with
cervical lymph node metastases and unknown primaries were
found below the clavicle. This is concordant with Jones
et al.,45 who found that up to 40% of patients with malig-
nant cervical lymph nodes had primary tumors outside of
the head and neck (most commonly in the lungs).
5. Conclusions
– PET imaging (FDG PET scan and FDG PET–CT scan) has
high sensitivity, speciﬁcity and accuracy for the detection of
unknown primary tumors with cervical lymph node metas-
The role of FDG PET in the diagnosis of occult primary with cervical lymph node metastases: A meta-analysis study 15tases indicating the existence of few false-negative and
positive results, an important feature in the management
of oncologic patients that could suggest its utility in the ini-
tial stages of the management process.
– FDG PET and PET/CT revealed similar detection rates for
unknown primary tumors with cervical lymph node metas-
tases. Detection rates with CT were substantially lower.
Thus, inclusion of functional data (PET scan or PET/CT)
for the assessment of CUP with cervical lymph node metas-
tases must be recommended.
Recommendations
Multi-center prospective randomized double blind controlled
trials comprising larger patient cohorts are required to deﬁ-
nitely determine the role of PET imaging (PET and PET–
CT) in diagnosis of occult primary with cervical lymph node
metastases.
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